Silence Therapeutics plc (SLN)
About Silence Therapeutics plc
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $559.0K
- Net income
- -$88.6M
- Total assets
- $131.4M
- Market cap
- $291.4M
- Gross margin
- 61.5%
- Operating margin
- -16292.8%
- Net margin
- -15851.9%
Source: SEC EDGAR · updated Jun 8, 2026
Financial statements
Income statement
- Revenue
- $559.0K
- Cost of revenue
- $215.0K
- Gross profit
- $344.0K
- Operating expenses
- $91.4M
- Operating income
- -$91.1M
- Income tax
- $11.0K
- Net income
- -$88.6M
- EPS (basic)
- $-0.63
- EPS (diluted)
- $-0.63
Balance sheet
- Total assets
- $131.4M
- Current assets
- $118.7M
- Total liabilities
- $69.1M
- Current liabilities
- $13.6M
- Shareholders’ equity
- $62.3M
Cash flow
- Operating cash flow
- -$62.3M
- Investing cash flow
- -$48.0M
- Financing cash flow
- $15.0K
- Net cash flow
- -$110.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $291.4M
- EPS (diluted)
- $-0.63
- Shares outstanding
- 26.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 8, 2020
Silence Therapeutics plc (SLN) Stock Price
- Reported a net loss of $88.6M in FY2025.
- Gross margin of 61.5%, net margin -15851.9%.
- Trading 7% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Silence Therapeutics plc.
Write a review
News about Silence Therapeutics plc
News & sentiment via Polygon.io
Silence Therapeutics plc: frequently asked questions
Is Silence Therapeutics plc an American company?
Silence Therapeutics plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Silence Therapeutics plc publicly traded?
Yes — Silence Therapeutics plc is a publicly traded company. Its stock trades under the ticker symbol SLN on the NASDAQ.
What does Silence Therapeutics plc do?
Silence Therapeutics plc is an American Pharmaceuticals company in the Health & Beauty sector.
